Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests

Annals of Oncology

Volumn 9, Issue 4, 1998, Pages 357-364

  Parchment, R E ^a   Gordon, M ^b   Grieshaber, C K ^c   Sessa, C ^d   Volpe, D ^c   Ghielmini, M ^d  

^a WAYNE STATE UNIVERSITY   (United States)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

CFU GM; Hematotoxicity; in vitro; Myelosuppression; Neutropenia; Phase I clinical trial; Prediction model; Validation

Indexed keywords

CAMPTOTHECIN; CYTOTOXIC AGENT; PYRAZINAMIDE; TALLIMUSTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; COLONY FORMING UNIT GM; HEMATOPOIETIC CELL; MAXIMUM ALLOWABLE CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

EID: 0031800079     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008245906772     Document Type: Review

References (23)

1. Gordon MY. Human haemopoietic stem cell assays. Blood Rev 1993; 7: 190-7.
2. Gordon MY. The origin and development of neutrophils. Handbook of Immunopharmacology. Academic Press 1994; 5-26.
3. Bruce WR, Meeker BE, Valeriote FA. Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colonyforming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 1966; 37: 233-45.
4. Volpe DA, Du DL, Zurlo MG et al. Comparative in vitro myelotoxicity of FCE 24517, a distamycin derivative, to human, canine and murine 6. hematopoietic progenitor cells. Invest New Drugs 1992; 10: 255-61.
5. Volpe DA, Tomaszewski JE, Parchment RE et al. Myelotoxic effects of the bifunctional alkylating agent bizelesin to human, canine, and murine myeloid progenitor cells. Cancer Chemother Pharmacol 1996; 39: 143-9.
6. Deldar A, Parchment RE. Preclinical hematological risk assessment for pharmaceutical products: Animal models and in vitro studies. In Bloom JC (ed): Volume 4, Toxicology of the Hematopoietic System: Sipes GI, McQueen CA, Gandolfi AJ (eds): Comprehensive Toxicology 1997; 303-20.
7. Grever MR, Grieshaber CK. Toxicology by organ system. In Holland JF, Frei E, Bast BC et al. (eds): Cancer Medicine (4th edition). Philadelphia: Lea and Febiger 1997.
8. Parchment RE, Murphy MJ Jr. Human hematopoietic stem cells: Laboratory assessment and response to injury. In Bloom JC (ed): Volume 4. Toxicology of the Hematopoietic; Sipes GI, McQueen CA, Gandolfi AJ (eds): Comprehensive Toxicology 1997; 335-61.
9. Parchment RE. Alternative testing systems for evaluating non-carcinogenic, hematologic toxicity. Environ Health Perspectives 1998; 106 (Suppl 2): in press.
10. Freireich EJ, Gehan EA, Rall DP et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966; 50: 219-44.
11. Collins JM, Chabner BA, Grieshaber CK. Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst 1990; 82: 1321-6.
12. Parchment RE, Huang M, Erickson-Miller CL. Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning. Toxicol Pathol 1993; 21: 241-50.
13. Gribaldo L, Bueren J, Deldar A et al. The use of in vitro systems for evaluating haematotoxicity. ECVAM workshop report 14. Alternatives to Laboratory Animals (ATLA) 1996; 24: 211-31.
14. Erickson-Miller CL, May R, Tomaszewski J et al. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother Pharmacol 1997; 39: 467-72.
15. Gianni L, Bonadonna G, Collins JM et al. Pharmacology and clinical toxicity of 4′-iodo-4′-deoxydoxorubicin: An example of successful application of pharmacokinetics to dose escalation in phase I trials. J Natl Cancer Inst 1990; 82: 469-77.
16. Parchment RE, Volpe DA, LoRusso PM et al. An in vivo-in vitro correlation of the myelotoxicity of 9-methoxypyrazoloacridine (PZA, NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrow. J Natl Cancer Inst 1994; 86: 273-80.
17. Du DL, Volpe DA, Grieshaber CK, Murphy MJ. In vitro myelotoxicity of 2′,3′-dideoxynucleosides on human hematopoietic progenitor cells. Exp Hematol 1990; 18: 832-6.
18. Du DL, Volpe DA, Grieshaber CK, Murphy MJ. L-phenylalanine mustard (L-PAM) and L-buthionine sulfoximine (L-BSO): Effects on murine and human hematopoietic progenitor cells in vitro. Cancer Res 1990; 50: 4038-43.
19. Du DL, Volpe DA, Grieshaber CK, Murphy MJ. In vitro toxicity of 3′-azido-3′-deoxythymidine (AZT), Carbovir and 2′,3′-dideoxythymidinene (d4T) to human and murine hematopoietic progenitor cells. Brit J Haematol 1992; 80: 437-45.
20. Volpe DA, Du DL, Verhoef V, Murphy MJ. Myelotoxicity of Rifabutin and AZT (3′-azido-3′-deoxythymidine), alone and in combination, to human hematopoietic progenitor cells in vitro. Pathobiology 1993; 61: 77-82.
21. Ghielmini M, Bosshard G, Capolongo L et al. Estimation of the haematological toxicity of minor grove alkylators using tests on human cord blood cells. Br J Cancer 1997; 75: 878-83.
22. Murphy MJ Jr, Fushimi F, Parchment RE, Barberá-Guillem E. Automated imaging and quantitation of tumor cells and CFU-GM colonies in microcapillary cultures: Toward therapeutic index-based drug screening. Invest New Drugs 1996; 13: 303-14.
23. Kearns CM, Gianni L, Egorin MJ. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 1995; 22 (Suppl 6): 16-23.